Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

Inclusion Criteria: * Measurable disease by CT or MRI. * At least 1 "target lesion" to be used to assess response as defined by GOG RECIST criteria. * ECOG performance status of 0 or 1. * Patient provides voluntary written informed consent. * At least 18 years of age. * Negative serum pregnancy test. * Recovered from any recent surgery for at least 30 days and is free of active infection. * Received the following prior therapy at time of enrollment: * Must have had 1 prior platinum-based chemotherapeutic regimen containing carboplatin, cisplatin or organoplatinum. Initial therapy may have included high-dose therapy, consolidation, or extended therapy. Patient should be defined as recurrent or progression of disease within 6 months of last platinum chemotherapy. * May have had 1 additional cytotoxic or non-cytotoxic chemotherapy regimen. * Must have adequate hematologic and hepatic function. Exclusion Criteria: * Previously received bevacizumab. * History of other invasive malignancy with the exception of nonmelanoma skin cancer. * ECOG performance status of 2, 3, or 4. * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study. Patient must be bevacizumab naïve. * Blood pressure of \>150/100 mm Hg on antihypertensive medications. * Prior history of hypertensive crisis or hypertensive encephalopathy. * Diagnosed with unstable angina per NYHA or Grade 2 or greater congestive heart failure. * History of myocardial infarction within 6 months of enrollment. * History of stroke or transient ischemic attack within 6 months prior to study enrollment. * Clinically significant vascular disease (e.g., aortic aneurysm, aortic dissection)or symptomatic peripheral vascular disease. * Bleeding diathesis or coagulopathy. * Presence of CNS or brain metastases. * Pre-existing peripheral neuropathy of Grade ≥ 2. * A major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study. * A partial or complete small or large bowel obstruction demonstrated radiologically within 3 months prior to study enrollment. * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment. * Positive pregnancy test or is lactating. * History of abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months prior to study enrollment. * Serious, non-healing wound, ulcer, or bone fracture. * Serious intercurrent medical or psychiatric illness, including serious active infection. * Inability to comply with study and/or follow-up procedures. * Life expectancy of less than 12 weeks. * Proteinuria at screening as demonstrated by either: * Urine protein:creatinine (UPC) ratio ≥ 1.0 at screening OR * Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible). * Known hypersensitivity to any component of bevacizumab.